WCP: Olanzapine-Fluoxetine Better Than Olanzapine Alone For Psychotic Depression
Unregistered User
If this is not your name, click here.
Contact Us | Order Now | Journals | Bookstore | Register a colleague
 
  SEARCH  
News
Bookstore
Medline
The Web
Meetings & Congresses
Complete Doctor's Guide
 


 EXPLORE :
 news  All News
 webcasts All Webcasts
 All cases All Cases
 Meetings All Meetings & Congresses
 Medical All Medical Resources

top





New drugs / indications

English Dictionary

Medical Dictionary

Thesaurus



Warning | Privacy | Awards



 Favourite Journals 

Click here to choose your favourite journals


 Favourite Sites 

Click here to choose your favourite sites


 Languages 



  




WCP: Olanzapine-Fluoxetine Better Than Olanzapine Alone For Psychotic Depression

By Bruce Sylvester

Special to DG News

YOKOHAMA, JAPAN -- August 28, 2002 -- Patients treated with olanzapine-fluoxetine combination treatment for psychotic major depression appear to have significantly greater improvement over olanzapine alone or placebo.

Researchers presented the findings at the World Conference on Psychiatry here.

"This study nicely illustrates that when you use a combination of olanzapine and fluoxetine, you are able to get a synergized effect," said Sanjay Dube, MD, medical director of the Olanzapine-Fluoxetine Combination Team at Lilly Research Laboratories, Indianapolis, Indiana, United States.

Researchers compared olanzapine-fluoxetine (OFC) to olanzapine or placebo in two 8-week double-blind trials with a 48-week open-label extension phase. The investigators randomised 249 subjects with psychotic depression into three treatment groups. Efficacy was evaluated with the Hamilton Anxiety and Depression - 24 (HAMD-24) scale.

Response rate for the OFC group was significantly greater (56 percent) than for olanzapine (36 percent) or placebo (30 percent).

Median time to response for OFC patients was significantly better (12 days) than placebo (20 days), and equal to olanzapine (12 days).

In the extension phase, 71 percent of OFC responders maintained their response. Significantly more OFC partial responders (defined as 25 percent total score decrease at two weeks) reached a full endpoint response compared with olanzapine or placebo (64 percent, 35 percent, 32 percent, respectively).

At endpoint, there were no significant differences in vital signs between the groups. Mean weight gain for OFC of 2.74 kg was similar to olanzapine at 3.79 (p=0.160) and greater than for placebo at .39 kg. (p=001).

There were no statistically significant differences between treatment groups on any scale of extrapyramidal symptoms

"With OFC therapy we have a safe combination with a good clinical effect," Dr. Dube added.

E-mail this page
to a friend or colleague!
To print,
use this version




Any question regarding a medical diagnosis, treatment, referral, drug availability or pricing should be directed to either a licensed physician or to the product's manufacturer.

If you have any technical questions or other concerns about this site, feel free to contact us at webmaster@docguide.com.

All contents Copyright (c) 1995- Doctor's Guide Publishing Limited. All rights reserved.


Employment opportunities | Partnering opportunities